Anika Therapeutics Inc (NASDAQ:ANIK) Shorted Shares Strengthened By 2.92%

May 16, 2018 - By Matthew Richard

Anika Therapeutics, Inc. (NASDAQ:ANIK) Corporate Logo

Big Money Sentiment decreased to 1.37 in 2017 Q4. It has change of 0.05, from 2017Q3’s 1.42. The ratio worsened due to Anika Therapeutics, Inc. positioning: 12 sold and 45 reduced. 24 funds bought stakes and 54 increased stakes. Investors holded 12.29 million in 2017Q3 but now own 12.26 million shares or 0.18% less.
11,466 were accumulated by Amer Intl Grp. Ami Asset Mngmt reported 276,041 shs or 1.03% of all its holdings. Bb&T Ltd Liability Corp invested in 14,593 shs or 0.01% of the stock. Prudential Financial has invested 0% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). First Quadrant L P Ca accumulated 0.01% or 13,400 shs. Tudor Inv Corp Et Al reported 0.02% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). Mutual Of America Capital Ltd Limited Liability Company invested in 50,467 shs. 79 are held by Loomis Sayles And L P. Creative Planning holds 8,229 shs or 0% of its capital. Thompson Davis Incorporated owns 0.05% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 400 shs. Ameriprise has invested 0% of its capital in Anika Therapeutics, Inc. (NASDAQ:ANIK). D E Shaw And reported 127,187 shs. Regions Fincl Corporation holds 719 shs. The Colorado-based Alps Advisors has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). State Board Of Administration Of Florida Retirement Systems owns 0% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 7,943 shs.

Change of 2.92% for Anika Therapeutics Inc (NASDAQ:ANIK)’s shorted shares was noted. FINRA announced shorted shares of ANIK’s total 1.20M shares. The 1.17 million previous shares are up with 2.92%. With Average volume 140,800, ANIK’s former position will take 9 days to recover. Anika Therapeutics Inc float short is 8.36%.

Ticker’s shares touched $40.09 during the last trading session after 5.09% change.Anika Therapeutics, Inc. has 470,688 shares volume, 252.83% up from normal. ANIK is uptrending and has moved 15.35% since May 16, 2017. ANIK outperformed the S&P500 by 3.80%.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally.The firm is valued at $591.14 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology.19 is the P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

A total of 3 analysts rate Anika Therapeutics Inc (NASDAQ:ANIK) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ANIK) has 4 ratings reports on May 16, 2018 according to StockzIntelligence. On Friday, February 23 the stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) has “Market Perform” rating given by Barrington Research. On Wednesday, January 24 the company was upgraded by First Analysis. On Friday, May 4 Barrington Research upgraded Anika Therapeutics, Inc. (NASDAQ:ANIK) to “Outperform” rating.

For more Anika Therapeutics, Inc. (NASDAQ:ANIK) news released recently go to: Seekingalpha.com, Globenewswire.com, Businesswire.com, Benzinga.com or Benzinga.com. The titles are as follows: “J&J cost cutting plan may pressure suppliers – Bloomberg” released on April 17, 2018, “Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest …” on May 01, 2018, “Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology …” with a publish date: May 08, 2018, “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” and the last “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” with publication date: April 29, 2018.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.